logo-loader
FinanceBanks
Hiscox

Hiscox slides after first-half of 2019 sees a rise in claims

"As ever, the results of the half-year are no indication of the results of the full year, so as we approach hurricane season there is still potential for the wind to blow us off course," said Robert Childs, the chairman of Hiscox.

Miami hurricane
Hurricane season will soon be upon us

Hiscox Ltd (LON:HSX) shares dipped on Monday morning despite the Lloyd’s of London insurer delivering interim profits at the higher end of its guidance range.

Profit before tax in the first half of 2019 rose to US$168.0mln from US$162.7mln the year before, not far off the top end of the US$150mln – US$170mln guidance issued earlier this month; before that revised guidance, analysts had been expecting a profit figure of around US$190mln.

READ Hiscox profit warning reduces buffers ahead of the hurricane season

Gross premiums written edged up to US$2,337.5mln from US$2,228.8mln a year earlier.

The group’s combined ratio – a measure of how shrewdly the company is choosing who and what to underwrite (a lower figure is better) – rose to 98.8% from 87.9% in the first half of last year.

The interim dividend has been nudged up to 13.75 cents from 13.25 cents the previous year.

The group said it experienced a higher volume of claims in the first half of 2019 than the same period last year.

"Hiscox delivered a profit of US$168 million for the first half despite a more challenging claims experience. Looking ahead, with six consecutive quarters of rate growth in some Lloyd's business, the market is in a better position than it has been for some time,” claimed Bronek Masojada, the chief executive officer of Hiscox.

“In retail, we will continue to invest in our infrastructure and marketing to drive sustainable growth. Our strategy of diversification gives us options," he added.

Hiscox shares were down 1.5% at 1,745p in early deals.


 

Quick facts: Hiscox

Price: £16.36

Market: AIM
Market Cap: £4.72 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

2 days, 10 hours ago

2 min read